 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates in Patients With Negative Predictors of Response to Treatment: an Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies
|
| |
| |
Reported by Jules Levin
DDW May 22-24 San Diego, CA
Nancy Reau1, Kosh Agarwal2, Keyur Patel3, Didier Samuel4, Marc Bourliere5, Ziad H. Younes6, Timothy R. Morgan7, Simone Strasser8,
Barbara Leggett9, Lin Liu10, Xiao Ding10, John McNally10, Anu Osinusi10, Bradley Collins10, Sarjita Naik10, Macky Natha10, Diana Brainard10, John McHutchison10, Nezam Afdhal11
1Rush University Medical Center, Chicago, IL, USA; 2Institute of Liver Studies, Kings College Hospital, London, UK; 3University Health Network Liver Clinic, Toronto, Canada; 4Centre Hepato-Biliaire, Villejuif, France; 5Hôpital Saint Joseph, Marseille, France; 6GastroOne, Germantown, TN, USA; 7VA Long Beach, Long Beach, CA, USA;
8Royal Prince Alfred Hospital, Camperdown, NSW, Australia; 9Royal Brisbane and Women's Hospital, Brisbane, Australia; 10Gilead Sciences, Inc., Foster City, California, USA; 11Beth Israel Deaconess Medical Center, Boston, USA
Su1413
|
| |
|
|
|
|
|
